Abstract
Atherosclerosis has been recognized as an inflammatory disease. The innate and adaptive immunity mechanisms are involved in atherogenesis. Low-grade inflammation is associated with innate immunity activation. The CRP has been proposed as the best indicator of low-grade inflammation and a predictor of cardiovascular events. A triumvirate of targets in the prevention of CVD are: LDL-C aggressive lowering, HDL-C increasing and CRP lowering. The statins role in lipids and CRP lowering is well established. Moreover, statins may be beneficial in many other inflammatory immune conditions. Among PPAR-α agonists, anti-inflammatory properties of fenofibrate are the best demonstrated. PPAR-γ agonists (thiazolidinediones) pleiotropic effects are also promising. PPAR α/γ agonists have been proved to cause severe side effects. Ezetimibe exerts beneficial anti-inflammatory actions when administered with statins. Colesevelam, a novel bileacid sequestrant has beneficial lipid-lowering and anti-inflammatory actions. CETP and ACAT inhibitors actions call for further studies. Inhibition of CRP, CRP-targeted antisenses, HDL-particle modification and immunomodulation of atherosclerosis are possible novel approaches in atherosclerosis treatment and prevention.
Keywords: Atherosclerosis, inflammation, immune system, CRP, statins, fibrates
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Lipid Lowering Agents, Inflammation and Atherosclerosis
Volume: 7 Issue: 3
Author(s): Marlena Broncel, Marzena Kozirog and Julita Chojnowska-Jezierska
Affiliation:
Keywords: Atherosclerosis, inflammation, immune system, CRP, statins, fibrates
Abstract: Atherosclerosis has been recognized as an inflammatory disease. The innate and adaptive immunity mechanisms are involved in atherogenesis. Low-grade inflammation is associated with innate immunity activation. The CRP has been proposed as the best indicator of low-grade inflammation and a predictor of cardiovascular events. A triumvirate of targets in the prevention of CVD are: LDL-C aggressive lowering, HDL-C increasing and CRP lowering. The statins role in lipids and CRP lowering is well established. Moreover, statins may be beneficial in many other inflammatory immune conditions. Among PPAR-α agonists, anti-inflammatory properties of fenofibrate are the best demonstrated. PPAR-γ agonists (thiazolidinediones) pleiotropic effects are also promising. PPAR α/γ agonists have been proved to cause severe side effects. Ezetimibe exerts beneficial anti-inflammatory actions when administered with statins. Colesevelam, a novel bileacid sequestrant has beneficial lipid-lowering and anti-inflammatory actions. CETP and ACAT inhibitors actions call for further studies. Inhibition of CRP, CRP-targeted antisenses, HDL-particle modification and immunomodulation of atherosclerosis are possible novel approaches in atherosclerosis treatment and prevention.
Export Options
About this article
Cite this article as:
Broncel Marlena, Kozirog Marzena and Chojnowska-Jezierska Julita, Lipid Lowering Agents, Inflammation and Atherosclerosis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (3) . https://dx.doi.org/10.2174/187152308785699254
DOI https://dx.doi.org/10.2174/187152308785699254 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Syntheses and Antitumor Properties of Furoxan Derivatives
Current Organic Chemistry Hypertension and Endothelial Dysfunction: Therapeutic Approach
Current Vascular Pharmacology Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Total Polyphenols and Bioactivity of Seeds and Sprouts in Several Legumes
Current Pharmaceutical Design Experimental Antioxidant Biotherapy for Protection of the Vascular Wall by Modified Forms of Superoxide Dismutase and Catalase
Current Pharmaceutical Design Dyslipidemia as a Risk Factor for Erectile Dysfunction
Current Medicinal Chemistry Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Safety and Efficacy of Novel Oral Anticoagulants: A Comparison to Vitamin K Antagonists
Cardiovascular & Hematological Agents in Medicinal Chemistry Red Blood Cells as Modulators of T Cell Growth and Survival
Current Pharmaceutical Design Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets The Role of 18FDG PET/CT in the Assessment of Endocarditis, Myocarditis and Pericarditis
Current Radiopharmaceuticals Synthesis, Characterization and Evaluation of Gemfibrozil-Stilbene Hybrid as Antioxidant Agent
Letters in Drug Design & Discovery A1 Receptors Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Preconditioning with Chronic Cerebral Hypoperfusion Reduces a Focal Cerebral Ischemic Injury and Increases Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 and Matrix Metalloproteinase-2 Expression
Current Neurovascular Research Oxidative Stress in Atherosclerosis Development: The Central Role of LDL and Oxidative Burst
Endocrine, Metabolic & Immune Disorders - Drug Targets AAV Vectorization of DSB-mediated Gene Editing Technologies
Current Gene Therapy Editorial: Inflammation and Heart Diseases
Current Pharmaceutical Design Cigarette Smoking in Methadone Maintained Patients: An Up-to-Date Review
Current Drug Abuse Reviews Ezetimibe and Its Inhibitory Effects on Intestinal Cholesterol Absorption
Vascular Disease Prevention (Discontinued)